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Background: It is known that the new membrane-bound estrogen receptor GPER-1 acts suppressive in breast
cancer cells and its expression decreases during disease progression. This study was conducted to evaluate the
GPER-1 expression in ovarian cancer and its correlation with progression. Its function was tested in vitro in ovarian
cancer cells.
Patients and methods: GPER-1 expression was analyzed by immunohistochemistry in 35 benign ovarian tumors,
35 tumors of low-malignant potential and in 124 ovarian cancers. GPER-1 expression was correlated to the
prospectively evaluated disease-free survival of ovarian cancer patients. We also tested GPER-1 expression in ovarian
cancer cells and the effect of GPER-1 stimulation on cell growth.
Results: GPER-1 expression was significantly lower in ovarian cancer tissue than in benign and low-malignant
ovarian tumors. GPER-1 expression was observed in 83.1% of malignant tumors and was higher in early stage
cancers and tumors with high histological differentiation. GPER-1 expression was associated with favourable clinical
outcome. The difference in 2-year disease-free survival by GPER-1 expression was significant, 28.6% for GPER-1
negative and 59.2% for GPER-1 positive cases (p = 0.002). GPER-1 expression was observed in SKOV-3 and OVCAR-3
ovarian cancer cell lines. G-1, a selective GPER-1 agonist, suppressed proliferation of the two cell types via inhibition
of cell cycle progression in G2/M phase and stimulation of caspase-dependent apoptosis. The blockade in G2/M
phase was associated with increased expression of cyclin B1 and Cdc2 and phosphorylation of histone 3.
Conclusion: GPER-1 emerges as a new tumor suppressor with unsuspected therapeutic potential for ovarian
cancer.
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Ovarian cancer is a common neoplasm in Western
countries and more than 70% of all diagnoses are in ad-
vanced stage [1,2]. The heterogeneity of ovarian cancer
forces the researcher to find new strategies and targets
to individualize the therapy of this common disease [3].
Recently the G-protein-coupled receptor 30 was claimed
to be a new membrane-bound G-protein-coupled
estrogen receptor-1 (GPER-1) involved in the rapid* Correspondence: atanas.ignatov@gmail.com
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reproduction in any medium, provided the ornongenomic effects of estrogen in normal and cancer
tissue [4]. It belongs to the family of G-protein-coupled
receptors (GPCRs) and acts independently of estrogen
receptor (ER) α and ERβ [4]. GPER-1 stimulation is as-
sociated with increased cAMP production assuming a
coupling of GPER-1 to Gαs [5]. Moreover, GPER-1 acti-
vation leads to activation and release of heparin-bound
growth factor (HB-EGF), which in turn activates the epi-
dermal growth factor receptor (EGFR) followed by phos-
phorylation of MAPK [6]. However, the physiological
and pathophysiological function of GPER-1 remains in-
completely discovered.
Despite the fact that GPER-1 can mediate the prolifer-
ative effects of estrogen in many estrogen-related can-
cers, we and others have demonstrated that GPER-1 canl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Moreover, we have recently found that GPER-1 down-
regulation in breast cancer tissue is associated with poor
clinical outcome [12].
The role of GPER-1 in ovarian carcinogenesis is only
particularly and very controversial studied. Smith and
co-workers have shown in 89 ovarian cancer patients
that GPER-1 expression is associated with poor survival
[13]. In contrast, Kolkova and co-workers have not
found any correlation between GPER-1 expression and
survival of 152 patients with ovarian cancer [14]. A third
research group has found that GPER-1 expression pre-
dicts lower survival of 150 ovarian cancer patients only
by co-expression with epidermal growth factor receptor
(EGFR) [15]. In vitro studies provide also controversial
data regarding GPER-1 effect on cell growth [16], adding
confusion to the role of GPER-1 in ovarian cancer.
This study was undertaken to put more clearance in
the role of GPER-1 in ovarian tumor biology. We inves-
tigated GPER-1 protein expression in benign and malig-
nant ovarian tumors. GPER-1 expression was correlated
to clinicopathological characteristics and clinical out-
come of ovarian cancer patients, which was assessed
prospectively. In addition, the effect of GPER-1 stimula-
tion in ovarian cancer cells was assayed via its specific
agonist G-1.
Patients and methods
Patients and tissue samples
The data of 35 patients with benign ovarian tumors and
35 patients with ovarian tumors of low malignant poten-
tial (LMP), who had been admitted to the Department
of Obstetrics and Gynecology, Otto-von-Guericke
University, Magdeburg, Germany from 1999 to 2011,
were selected by retrospective analysis. Additionally, tis-
sue from 124 ovarian cancer patients was obtained at
the operation in the Department of Obstetrics and
Gynecology, University Clinic of Magdeburg, Germany
in the period between 2005 and 2010. The study was
approved by the Research and Ethical Committee of
Otto-von-Guericke University, Magdeburg, Germany.
The expression analysis of GPER-1 in ovarian cancer tis-
sue was designed as a prospective monocentre cohort
study. The primary outcome of the study was the correl-
ation of GPER-1 expression and the 2-year disease-free
survival (DFS) of ovarian cancer patients. Outcome was
measured as DFS, according to the International Union
Against Cancer (UICC) criteria [17]. Secondary outcome
was the correlation of GPER-1 expression in ovarian
cancer tissue and clinicopathological characteristics. The
minimal follow-up period was 24 months. The inclusion
criteria were diagnosis of ovarian cancer, no previous
treatment with chemotherapy and no history of other
carcinomas. Exclusion criteria included a previoushistory of adjuvant anti-hormonal or cytostatic therapy,
incomplete adjuvant chemotherapy, no sufficient mater-
ial for detection of GPER-1 expression and incomplete
24 months follow-up data. One hundred thirty seven
eligible patients were enrolled in the study. Thirteen pa-
tients were secondary excluded because of lost of follow-
up (7 patients), incomplete chemotherapy (3 patients)
and detection of second cancer during the follow-up
time (3 patients). All ovarian cancer patients underwent
adjuvant platinum-based chemotherapy.
The median age at the time of primary diagnosis was
62 years (range 12–87 years) in the group of patients
with benign ovarian tumors, 52 years (range 21–81 years)
in the group of patients with LMP tumors and 64 years
(range 20–86 years) in the group of patients with ovarian
cancer.Immunohistochemistry
GPER-1 expression was analyzed as previously described
[18]. Briefly, sections of formalin-fixed and paraffin-
embedded ovarian tumors, including benign ovarian cyst,
tumors of low malignant potential (LMP) and malignant
ovarian cancer specimens were investigated. The immuno-
staining was performed with affinity-purified rabbit anti-
body against GPER-1 (SP4677P; Acris antibodies, Herford,
Germany) diluted 1:500. The slides were counterstained
with hematoxylin and cover slipped after being embedded
in mounting medium. The specificity of the antibody has
been already proven [18]. Moreover, we assayed GPER-1
expression on 15 representative tissue samples of ovarian
carcinoma with a second antibody against GPER-1 (sc-
48524-R, Santa Cruz, Heidelberg, Germany diluted 1:500).
The obtained expression pattern with the two antibodies
was very similar and confirms again their specificity (data
not shown).
GPER-1 expression was classified as already de-
scribed [18,19], according to the following grading sys-
tem: staining extensity was categorized as 0 (no
positive cells), 1 (<10% positive cells), 2 (10-50% posi-
tive cells), or 3 (>50% positive cells), and staining in-
tensity was categorized as 0 (negative), 1 (weak), 2
(moderate), or 3 (strong). The individual categories
were multiplied to give a total immunohistochemical
score (IHC). IHC score ranged between 0 and 9.
GPER-1-positive expression was defined for tumors
that showed an IHC ≥1. Representative example of
GPER-1 expression is shown in Figure 1.Cell culture and treatment
Ovarian cancer cell lines SKOV-3 and OVCAR-3 were
obtained from Cell Lines Services (Germany) and routinely
cultured in DMEM/F12 (PAN Biotech) supplemented with
10% FBS, 100U/ml penicillin and 100 μg/μl streptomycin at
Figure 1 Paraffin-embedded ovarian tumor tissue immunostained with GPER-1 antibody. GPER-1 immunostaining of ovarian cancer tissue:
(A) strong positive expression in benign ovarian tumor; (B) strong positive expression in tumor of low malignant potential; (C) negative, (D)
weak, (E) moderate and (F) strong positive staining of GPER-1 in ovarian cancer tissue. Original magnification: x 100.
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treated as indicated in the figure legends.Western blotting
Western blotting procedures were performed as previ-
ously described [18]. Briefly, the blots were incubated
overnight at 4°C with antibodies against GPER-1 (sc-
48524-R, Santa Cruz, Heidelberg, Germany, diluted
1:500), caspase-3 (ab13847, Abcam, Cambridge, UK, di-
luted 1:1000), cyclin B1(#4138, Cell signalling, Frankfurt
am Main, Germany, diluted 1:1000), Cdc2 (#9112, Cell
signalling, Frankfurt am Main, Germany, diluted 1:2000)
phosphoH3(Ser10) (#9701, Cell signalling, Frankfurt am
Main, Germany, diluted 1:2000) and for 2 h at room
temperature with antibody against β-actin (A5441,
Sigma Aldrich, Hamburg, Germany diluted 1:10000).
Peroxidase-conjugated anti-rabbit and anti-mouse anti-
bodies (Thermo Scientific, Waltham, MA, USA), diluted
1:2000 and 1:5000, were used as secondary antibodies
(2 h at room temperature), respectively.Cell cycle analysis and apoptosis assay
Cell lines were treated with 1 μM G-1 or vehicle control
for 48-72 h. Cell cycle distribution was analysed by
propidium iodide (PI) staining using flow cytometry.
Apoptosis was determined by using the FITC Annexin V
Apoptosis Detection Kit (BD, Heidelberg, Germany).MTT-viability assay
MTT-viability assay was performed as already described
[20]. Briefly, 2000 cells per well were seeded and cul-
tured in 96-well plate in growth medium. After 24 h the
cells were stimulated with indicated concentrations of
G-1, G-15 or DMSO as control for 5 days. This was
followed by a 3 h treatment with MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)
in the dark at 37°C. After removing the supernatants
and incubation in 150 μl lysis buffer (isopropanol
containing 4 mM HCl and 0,1% NP-40 ) cell viability
was determined by measuring the absorbance at 570 nm
(Synergy HT, BioTek, Germany).
Statistical analysis
The statistical calculations were performed using SPSS
Version 20.0 (SPSS, Chicago, IL, USA). An association
between GPER-1 expression and the tumor variables
was evaluated using the x2 test or Fisher’s exact test.
DFS analysis took into account those who died of ovar-
ian cancer-specific death or had a recurrence of disease
as a primary event. Patients who died of other causes
were censored. Survival was calculated using the
Kaplan-Meier method. The equality of survival curves
was tested by the log rank test. Univariate Cox propor-
tional hazard regression analysis was used to identify sig-
nificant prognostic factors. The prognostic significance
was confirmed by multivariate analysis. The statistical
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considered statistically significant. The comparison of
GPER-1expression between benign tumors, LMP tumors
and ovarian cancers was analyzed using nonparametric
paired test, and was performed with the Wilcoxon
signed rank sum test.
Results
GPER-1 protein expression in ovarian tumors and
correlation with clinical and pathologic features of
ovarian cancer
GPER-1 expression was assessed by immunohistochem-
istry in 35 benign ovarian tumors, 35 ovarian tumors of
low malignant potential (LMP) and 124 ovarian cancers.
GPER-1 expression was observed in all (100%) benign
ovarian tumors, in 34 of 35 (97.1%) tumors of LMP and
in 103 of 124 (83.1%) of ovarian cancers. GPER-1 ex-
pression was significantly lower in ovarian cancer com-
pared to the benign and tumors of LMP (p < 0.0001;
Figure 2A). The median IHC-score was 6 for benign and
tumors of LMP, whereas ovarian cancer tissue demon-
strated a median IHC-score of 2.
Next, we compared GPER-1 protein expression with
the clinicopathological features of ovarian cancer. GPER-
1 expression was significantly associated with the clinical
stage of disease (p = 0.032; Table 1). Loss of GPER-1 ex-
pression was more frequently observed in advanced
ovarian cancer. Moreover, a reduction of GPER-1 ex-
pression of approximately 20% was observed with de-
crease of histological differentiation (Table 1). However,
this correlation did not reach a significant level. There
was no correlation between GPER-1 immunostaining
and other tumor characteristics (Table 1). All this dataA 
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Figure 2 GPER-1 protein expression and clinical outcome. A) Protein e
ovarian cancer patients according to GPER-1 expression. The log rank test wsuggested a loss of expression of GPER-1 during ovarian
tumorigenesis.
GPER-1 expression and clinical outcome of ovarian
cancer patients
During the prospective follow-up time of 24 months we
observed 67 recurrences of cancer. There was a signifi-
cant difference in DFS between GPER-1-positive and
GPER-1-negative patients (Table 1). GPER-1 positivity
was associated with reduced rate of disease recurrence
(p = 0.008).
Univariate analysis revealed that GPER-1 expression
was a favorable prognostic factor for DFS (HR, 0.404;
95% CI, 0.233-0.732; p = 0.003) (Table 2). The 2-year
DFS was 28.6% for GPER-1-negative patients and 59.2%
for GPER-1-positive patients (p = 0.002; Figure 2B). After
adjustment for patient age, menopausal status, tumor
stage, lymph node status, histological grading, multivari-
ate analysis rendered GPER-1 as an independent, favor-
able prognostic factor in regard to DFS (HR, 0.569; 95%
CI, 0.317-0.991; p = 0.046) (Table 2). Tumor stage was
evaluated as an unfavorable independent prognostic fac-
tor (HR, 2.764; 95% CI, 1.590-3.751; p < 0.0001).
Effect of GPER-1 stimulation on ovarian cancer cell
proliferation
Next we wanted to test the effects of GPER-1 in vitro.
First of all, we analyzed the protein expression of
GPER-1 in SKOV-3 and OVCAR-3 ovarian cancer cells
by western blot (Figure 3A). MCF-7 breast cancer cells
were used as positive control. GPER-1 expression
was observed in the two ovarian cell lines. However,
OVCAR-3 cells demonstrated a 2-fold higher GPER-1B 
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Table 1 Characteristics of study cohort
Characteristic
N of
patients
GPER-1
p-value
Negative Positive
N (%) N (%)
Total 124 21 (16.9) 103 (83.1)
Age, years (range) 124 65 (30–84) 61 (20–85) 0.136
Menopausal status
premenopausal 16 1 (6.2) 15 (93.8)
postmenopausal 108 20 (18.5) 88 (81.5) 0.304
FIGO Stage
1 25 0 (0) 25 (100)
2 21 6 (28.6) 15 (71.4)
3 76 14 (18.4) 62 (81.6)
4 2 1 (50.0) 1 (50) 0.032
Lymph node status
negative 31 5 (16.1) 26 (83.9)
positive 18 3 (16.7) 15 (83.3) 1.000
Histological grading
1 18 0 (0) 18 (100)
2 38 7 (18.4) 31 (81.6)
3 68 14 (20.6) 54 (79.4) 0.112
Histology
serous 81 13 (16.0) 68 (84.0)
mucinous 16 3 (18.8) 13 (81.2)
endometrioid 13 2 (15.4) 11 (84.6)
clear cell 8 0 (0) 8 (100)
other 6 3 (50) 3 (50) 0.171
Recurrence (in 24 months)
no 57 4 (7.0) 53 (93.0)
yes 67 17 (25.4) 50 (74.6) 0.008
Table 2 Uni- and multivariate analysis in regard to DFS
Variable HR 95% CI P-value
Univariate analysis
GPER-1 expression 0.404 0.233-0.732 0.003
Age 1.010 0.990-1.031 0.322
Menopausal status 1.676 0.715-3.930 0.235
Tumor stage 3.023 1.774-5.150 <0.0001
Lymph node status 1.950 0.731-5.197 0.182
Histological grading 2.132 1.363-3.335 0.001
Multivariate analysis
GPER-1 expression 0.549 0.317-0.991 0.046
Tumor stage 2.764 1.590-3.751 <0.0001
Histological grading 1.576 0.982-2.531 0.060
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whether GPER-1 influences the growth of ovarian cancer
cells. Both ovarian cell lines were incubated with in-
creasing concentrations of GPER-1 specific agonist G-1.
A concentration-dependent inhibition of cell prolifera-
tion was observed (Figure 3B). The estimated IC50 value
was 3.9 μM and 0.8 μM for SKOV-3 and OVCAR-3
cells, respectively.
Furthermore, we wanted to exclude a possible cyto-
toxic effect of high G-1 concentrations. For this purpose
we incubated SKOV-3, OVCAR-3 and GPER-1-negative
HEK-293 cells with 1 μM G-1 for 5 days. As demon-
strated in Figure 4, G-1 did not change the proliferation
of HEK-293 in comparison to control-treated cells. It
suggested that G-1 inhibitory effect in SKOV-3 and
OVCAR-3 ovarian cancer cells due to specific activation
of GPER-1 and not to cytotoxic properties. To explore
the involvement of GPER-1 activation in G-1-inducedcell growth inhibition we extended our experiments
using G-15 a recently discovered GPER-1 receptor an-
tagonist [21]. Pre-incubation of SKOV-3 and OVCAR-3
cells with 1 μM G-15 was able to block the inhibitory ef-
fect of G-1 (Figure 4). As expected in GPER-1-negative
HEK-293 cells G-15 pre-incubation was not associated
with any changes in cell proliferation (Figure 4). All
these data suggested an involvement of GPER-1 in G-1
-induced proliferation effects.
GPER-1 activation by G-1 induced a cell-cycle arrest and
cell apoptosis in SKOV-3 and OVCAR-3 cells
We next tested by flow cytometry analysis whether
GPER-1 activation by G-1 results in abrogation of cell
cycle progression. Stimulation of ovarian cancer cells
with G-1 led to concentration-dependent accumulation
of SKOV-3 (Figure 5A) and OVCAR-3 (Figure 5B) cells
in apoptotic sub-G1 phase and decreased the cell num-
ber in G1 phase. Higher concentrations of G-1 were as-
sociated with additional block in G2/M phase.
To confirm the effect of GPER-1 on cell apoptosis
AnnexinV assay was applied. A concentration- and time-
dependent increase of cell apoptosis was observed in the
two cell lines after stimulation with G-1 (Figure 6). In
the SKOV-3 cell line we observed a concentration-
dependent increase of cell apoptosis by 1%, 3% and 7%
after 48 h stimulation with 500 nM, 700 nM and 1 μM G-1,
respectively (Figure 6A). After 72 h incubation duplication
of G-1-induced cell apoptosis was observed. In OVCAR-3
cells G-1 treatment caused even higher rates of cell apop-
tosis. After treatment with G-1 for 48 h in aforementioned
concentrations cell apoptosis reached a level of 7% 13%,
and 28%, respectively (Figure 6B). After 72 h stimulation
the rate of cell apoptosis increased to 13%, 30%, and 49%
after incubation with 500 nM, 700 nM and 1 μM G-1
respectively (Figure 6B).
These data suggested that GPER-1 might inhibit ovar-
ian cancer cell proliferation via simultaneous cell cycle
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cell cycle arrest and apoptosis in more details we exam-
ined the expression of different regulatory proteins in-
volved in cell cycle progression and apoptosis. After
stimulation of SCOV-3 (Figure 7A) and OVCAR-3
(Figure 7B) cells with 1 μM G-1 for indicated time, the
expression of cyclin B1 and Cdc2, the phosphorylation
of histone H3 and the cleavage of caspase-3 was mea-
sured by immunoblotting. In the two cell lines tested in
this study, we found that G-1-induced cell cycle arrest
and apoptosis was associated with up-regulation ofControl 1µM G-1 1µM G-1+ 1µM G-15
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Figure 4 GPER-1 specific antagonist G-15 abolished the
G-1-induced inhibitory effect in ovarian cancer cells.
GPER-1-positive SCOV-3 and OVCAR-3 ovarian cancer cells and
GPER-1-negative HEK-293 cells were incubated for 5 days with 1 μM G-1
with or without pre-treatment with 1 μM G-15 for 24 h and the cell
number was counted using MTT viability assay. Each experiment was
repeated at least three times. The results are expressed as means ± SD.cyclin B1 and Cdc2 protein expression. The phosphoryl-
ation of histone H3 was also observed (Figure 7). The
levels of cyclin B1 and Cdc2 protein expression started
to increase at 6 h after G-1 treatment, reached a peak
between 12 and 24 h followed by rapid decline (data not
shown). The phosphorylation of histone H3, indicative
for cells in mitotic phase, started to increase at 6 h after
stimulation of the cells with G-1 and peaked at 12 h
(Figure 7).
The caspase-3 cleavage product as result of its activa-
tion was observed in both cell lines after incubation with
G-1. The activation of caspase-3 started at 24 h after
GPER-1 activation and peaked around 48 h in the two
cell lines (Figure 7).
Discussion
This is the first report demonstrating the favourable role
of GPER-1 in ovarian cancer patients in regard to
disease-free survival (DFS). GPER-1 expression and
clinical outcome were investigated in a very homogenous
cohort of platinum-treated ovarian cancer patients.
GPER-1 expression was a favourable factor regarding 2-
year DFS in ovarian cancer patients. Moreover, GPER-1
expression decreased from benign to malignant ovarian
tumours. In vitro, GPER-1 stimulation was associated
with a significant increase of cellular apoptosis and cell
cycle arrest in ovarian cancer cells.
To date there are only few reports about GPER-1 and
clinical outcome of ovarian cancer patients providing
very confusing and controversial results. Smith and co-
workers have recently found that GPER-1 expression
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which is in the opposite to our observation. In this re-
port the median overall survival was significantly shorter
for patients expressing high levels of GPER-1. It is
remarkable, that this correlation was observed only in
adverse tumors but not for low grade tumors. Unfortu-
nately, the impact of GPER-1 on patient outcome has
not been confirmed via multivariate analysis. In the
aforementioned patient collective GPER-1 expression
significantly correlated with tumor stage and tumor
grading, two known prognostic factors in ovarian cancer
patients, which could explain the impact of GPER-1 on
survival. In our cohort of patients GPER-1 was inde-
pendent favourable prognostic factor even after adjust-
ment of other prognostic factors. Another plausible
explanation of the controversial results is a difference in
population studied. Interestingly, another research grouphas not found any correlation between GPER-1 expres-
sion on mRNA and protein level with clinical outcome
of ovarian cancer patients [14]. It is to note that in this
cohort of 150 patients GPER-1 was expressed in only
one third, whereas in our cohort more than 80% of the
invasive ovarian cancers expressed GPER-1. The differ-
ence might be explained by the specificity of the
antibodies used, the evaluation criteria of GPER-1 ex-
pression or by the fact that Kolkova et al. correlated
GPER-1 expression only to overall survival but not to
DFS [14]. Similar results were observed in analysis of
152 patients by Fjiwara et al. [15]. In these series GPER-
1 expression has not shown any correlation with overall
survival of ovarian cancer patients. However, the authors
stated that EGFR expression in combination with GPER-
1 predicts lower survival in patients with ovarian
cancer. This is in agreement with our recent results
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breast cancer cell lines [22]. The cross-talk between
GPER-1 and EGFR is associated with activation of com-
pletely different signalling pathways [5,6,23] and could
be responsible for the observed difference in survival
rates. In agreement with the results obtained by us in
the present study we have recently found that GPER-1 is
associated with better patient survival in breast cancer
patients [18] and have been recently confirmed for in-
flammatory breast cancer [24].
In accordance to expressional analyses, in vitro studies
revealed controversial results regarding cellular func-
tions of GPER-1. Since establishment of GPER-1 as an
estrogen receptor many reports demonstrated its stimu-
latory effect in breast, ovarian and endometrial cells
[23,25,26]. Nevertheless, numerous recent investigations
clearly demonstrated an inhibitory effect of GPER-1 in
various cell systems [7-11,16,27] and are in agreement
with our findings. G-1 inhibitory effect in these cells sys-
tems has been observed only in high concentrationssimilar to our results in ovarian cancer cells. The ab-
sence of G-1-induced inhibition in GPER-1-negative
HEK293 cells exclude a potential cytotoxic effect to the
cells.
GPER-1 stimulation inhibited ovarian cell proliferation
by inducing cell apoptosis and cell cycle arrest. We ob-
served an accumulation of cyclin B1 and Cdc2 regula-
tory proteins in G-1-treated ovarian cancer cells. This is
contradicting the results observed in breast and prostate
cancer cells where cyclin B1 and Cdc2 expression were
inhibited by G-1 stimulation [9,10]. Possible explanation
for this discrepancy could be the use of different cell
types or the fact that breast cancer cells and prostate
cancer cell were blocked in G1 [9] and G2 phase [10],
respectively. The suppression of Cyclin B1 and Cdc2 is
associated with G2 arrest, whereas the up-regulation of
the two proteins induced a cell accumulation in the M
phase [28]. Thus the G-1-induced activation of Cyclin
B1 and Cdc2 in ovarian cancer cells is associated with
progression in the G2 phase to M phase. It was
Ccyclin B1
cdc2
phospho-H3
ß-actin
SCOV-3 OVCAR-3
G-1 C G-1 C G-1
0h 6h 12h 24h
C G-1 C G-1 C G-1
0h 6h 12h 24h
C G-1 C G-1 C G-1
0h 12h 24h 48h
pro-caspase-3
ß-actin
caspase-3
C G-1 C G-1 C G-1
0h 12h 24h 48h
A B
Figure 7 GPER-1 specific agonist G-1 induced expression of cyclin B1 and Cdc2 regulatory proteins, phosphorylation of histone 3 and
cleavage of pro-caspase-3. SCOV-3 (A) and OVCAR-3 (B) ovarian cancer cells were incubated with medium (control) or 1 μM G-1 for indicated
times and the protein expression of cyclin B1, Cdc2 and caspase-3 as well as the phosphorylation of histone 3 were investigated by western blot
analysis. ß-actin was used as a loading control. Each experiment was repeated three times.
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histone H3, an important step occurring during G2 to
M transition [29], was significantly induced by G-1
activation. The perturbation of mitotic progression by
GPER-1 stimulation with consequent increased mitotic
duration could trigger caspase-3 cleavage and cell apop-
tosis. This phenomenon has been already described for
taxol and nocodazole, two microtubule inhibitors with
anticancer activity [28,30]. The inhibitory effect of
GPER-1 in ovarian cancer cells has been recently well
documented and is in accordance to our results. Henic
and co-workers have recently found that GPER-1 stimu-
lation attenuates the invasive properties of ovarian can-
cer cells [31].
Our results and the review of literature make us to
hypothesize that GPER is a potential tumor suppressor.
Tumor suppressors are known to be inactivated during
cancer progression [32] which was also observed for
GPER-1. The decreased expression of GPER-1 benign
and malignant ovarian tumors corroborates the pre-
sumption that GPER-1 might be a tumor suppressor.
This phenomenon was observed by us during the
breast cancer tumorigenesis and was confirmed by two
other groups [33,34]. We have found that GPER-1 isinactivated via promoter methylation in breast cancer
tissue and is re-expressed after treatment with de-
methylating agent 5-Aza (own not published data).
The most important finding of our study is the fact
that GPER-1 with its high expression of 80% in ovarian
cancer tissue could be an appropriate target for individu-
alized therapy of ovarian cancer. Our study provides
evidence that GPER-1 may be a tumor suppressor gene.
First, GPER-1 specific agonist inhibited ovarian cancer cell
proliferation by inducing cell apoptosis and partially cell
cycle arrest. Second, GPER-1 expression was found to be
down-regulated during ovarian cancer tumorigenesis.
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